(Q48887380)

16 February 2018

title

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor (English)

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

19 October 2022

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

19 October 2022

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

19 October 2022

author name string

van Vliet IM

1

1 reference

16 February 2018

den Boer JA

2

1 reference

16 February 2018

I. M. van Vliet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1638170

19 October 2022

J. A. den Boer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1638170

19 October 2022

H. G. Westenberg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1638170

19 October 2022

language of work or name

English

0 references

publication date

1 March 1992

1 reference

16 February 2018

full work available at URL

https://api.elsevier.com/content/article/PII:0924977X92900324?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

https://api.elsevier.com/content/article/PII:0924977X92900324?httpAccept=text/plain

19 October 2022

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

European Neuropsychopharmacology

19 October 2022

published in

1 reference

16 February 2018

volume

2

1 reference

16 February 2018

issue

1

1 reference

16 February 2018

page(s)

21-29

1 reference

16 February 2018

Social phobia: a comparative clinical study

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Effect of brofaromine and pargyline on human plasma melatonin concentrations

19 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Melatonin and cortisol increase after fluvoxamine

19 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine

19 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline

19 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

19 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

The treatment of social phobia. Real-life rehearsal with nonprofessional therapists.

19 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Treatment of social phobia with atenolol

19 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

The assessment of anxiety states by rating

19 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Development of a Rating Scale for Primary Depressive Illness

19 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Treatment of phobic states with antidepressants. A retrospective study of 246 patients

19 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

19 October 2022

Social phobia

18

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Psychopharmacological treatment of social phobia

19 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Social phobia. Review of a neglected anxiety disorder

19 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Phenelzine and atenolol in social phobia

19 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

The Classification of Phobic Disorders

19 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Different ages of onset in varieties of phobia

19 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

A Clinical Trial of Phenelzine in Anxiety Depressive and Phobic Neuroses

19 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl

19 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

19 October 2022

Severe social anxiety.

27

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients?

19 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Primary and secondary social phobia: psychopathologic and familial differentiations.

19 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection

19 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Phenelzine and exposure in the treatment of phobias

19 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Delineating social phobia

19 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

The determination of cortisol in human plasma: evaluation and comparison of seven assays

19 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety

19 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Symptomatic Treatment of Agoraphobia and Social Phobias: A Follow-up Study

19 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders

19 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain

19 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo

19 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

Kinetics of l-5-hydroxytryptophan in healthy subjects

19 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0924-977X(92)90032-4

19 October 2022

Identifiers

1 reference

16 February 2018

1 reference

16 February 2018